中文English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Issue 10
Oct.  2018
Turn off MathJax
Article Contents

Research advances in the application of antiviral drugs during pregnancy for blocking mother-to-child transmission of hepatitis B virus

DOI: 10.3969/j.issn.1001-5256.2018.10.032
Research funding:

 

  • Received Date: 2018-04-13
  • Published Date: 2018-10-20
  • Mother-to-child vertical transmission is an important route of transmission for hepatitis B virus ( HBV) infection in patients with chronic hepatitis B, and the rate of HBV infection increases with the increase in the mother's HBV viral load. Although active and passive immunoprophylaxis has been implemented for neonates at present, the rate of mother-to-child vertical transmission of HBV remains around 10%. Therefore, pregnant women with a high viral load should receive antiviral therapy to reduce the viral load, in order to prevent and block the mother-to-child transmission of HBV and reduce the incidence rate of chronic hepatitis B. By retrieving related literature in China and foreign countries, this article describes the safety and efficacy of antiviral agents during pregnancy and provides a reliable basis for guiding medication during pregnancy.

     

  • loading
  • [1]REDDY CV, FUNG S, BELING CD.The impact of vaccination and antiviral therapy on hepatitis B and hepatitis D epidemiology[J].PLo S One, 2014, 9 (10) :e110143.
    [2]MA L, ALLA NR, LI X, et al.Mother-to-child transmission of HBV:review of current clinical management and prevention strategies[J].Rev Med Virol, 2014, 24 (6) :396-406.
    [3]XU H, ZENG T, LIU JY, et al.Measures to reduce mother-tochild transmission of hepatitis B virus in China:A meta-analysis[J].Dig Dis Sci, 2014, 59 (2) :242-258.
    [4]SHI Z, LI X, MA L, et al.Hepatitis B immunoglobul in injection in pregnancy to interrupt hepatitis B virus mother-to-child transmission-a meta-analysis[J].Int J Infect Dis, 2010, 14 (7) :e622-634.
    [5]YUAN J, LIU J, XU A, et al.Antepartum immunoprophylaxis of three doses of hepatitis B immunoglobulin is not effetive:A singlecentre randomized study[J].J Vrial Hepat, 2006, 13:597-604.
    [6]ZHANG L, GUI XE, TETER C, et al.Effects of hepatitis B immunization on prevention of mother-to-infant transmission of hepatitis Bvirus and on the immune response of in fants towards hepatitis B vaccine[J].Vaccine, 2014, 32 (46) :6091-6097.
    [7]CHEN HL, LIN LH, HU FC, et al.Effects of maternal screening and universal immunization to prevent mother-to-infant transmission of HBV[J].Gastroenterology, 2012, 142 (4) :773-781.
    [8]Chinese Society of Hepatology and Chinese Society of Infectious Diseases, Chinese Medical Association.The guideline of prevention and treatment for chronic hepatitis B:a 2015 update[J].J Clin Hepatol, 2015, 31 (12) :1941-1960. (in Chinese) 中华医学会肝病学分会, 中华医学会感染病学分会.慢性乙型肝炎防治指南 (2015年更新版) [J].临床肝胆病杂志, 2015, 31 (12) :1941-1960.
    [9]XIA GL, GONG J, WANG JJ, et al.Efficacy of recombinant hepatitis B vaccine and low-dose hepatitis B immune globulin in preventing mother-infant transmission of hepatitis B virus infection[J].Chin J Epidemiol, 2003, 24 (5) :362-365. (in Chinese) 夏国良, 龚健, 王继杰, 等.重组乙型肝炎疫苗阻断乙型肝炎病毒母婴传播方案的保护效果评价[J].中华流行病学杂志, 2003, 24 (5) :362-365.
    [10]DEGLI ESPOSTI S, SHAH D.Hepatitis B in pregnancy:Challenges and treatment[J].Gastroenterol Clin North Am, 2011, 40 (2) :355-372.
    [11]ZOU H, CHEN Y, DUAN Z, et al.Virologic factors associated with failure to passive-active immunoprophylaxis in infants born to HBsAg-positive mothers[J].J Viral Hepat, 2012, 19 (2) :e18-e25.
    [12]KANG W, DING Z, SHEN L, et al.Risk factors associated with immunoprophylaxis failure against mother to child transmission of hepatitis B virus and hepatitis B vaccination status in Yunnan province, China[J].Vaccine, 2014, 32 (27) :3362-3366.
    [13]ELEFSINIOTIS IS, TSOUMAKAS K, KAPRITSOU M, et al.Liver function tests in viremic and nonviremic chronic hepatitis B virusinfected pregnant women:Importance of alanine aminotransferase/sodium ratio[J].Gastroenterol Nurs, 2013, 36:422-428.
    [14]WHO Guidelines Approved by the Guidelines Review Committee.WHO guidelines for the prevention, care and treatment of persons with chronic hepatitis B infection[S/OL].http://www.who.int/hepatitis/publications/hepatitis-b-guidelines/en/
    [15]JR BR, VERNA EC, PEREIRA MR, et al.Hepatitis B virus and human immunodeficiency virus drugs in pregnancy:Findings from the Antiretroviral Pregnancy Registry[J].J Hepatol, 2012, 57 (5) :953-959.
    [16]CHEN YH, CAO QF, HONG QY, et al.Effect of tenofovir disoproxil fumarate on serum FGF-23, β2-MG, Cys-C and RBPlevel in patients with chronic hepatitis B[J].Chin J Clin Pharmacol Ther, 2017, 22 (7) :799-804. (in Chinese) 陈勇华, 曹群奋, 洪琼怿, 等.替诺福韦酯治疗对慢性乙型肝炎患者血清FGF-23、β2-MG、Cys-C及RBP水平的影响[J].中国临床药理学与治疗学, 2017, 22 (7) :799-804.
    [17]PAN CQ, DUAN Z, DAI E, et al.Tenofovir to prevent Hepatitis Btransmission in mothers with high viral load[J].N Engl J Med, 2016, 374 (24) :2324-2334.
    [18]CHEN HL, LEE CN, CHANG CH, et al.Efficacy of maternal tenofovir disoproxil fumarate in interrupting mother-to-infant transmission of hepatitis B virus[J].Hepatology, 2015, 62 (2) :375-386.
    [19]BROWN RS, MCMAHON BJ, LOK ASF, et al.Antiviral therapy in chronic hepatitis B viral infection during pregnancy:A systematic review and meta-analysis[J].Hepatology, 2016, 63 (1) :319-333.
    [20]HEATHCOTE EJ, MARCELLIN P, BUTI M, et al.Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B[J].Gastroenterology, 2011, 140 (1) :132-143.
    [21]LOK AS, MCMAHON BJ.Chronic hepatitis B:Update 2009[J].Hepatology, 2009, 50 (3) :661-662.
    [22]TENNEY DJ, ROSE RE, BALDICK CJ, et al.Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naive patients is rare through 5 years of therapy[J].Hepatology, 2009, 49 (5) :1503-1514.
    [23]YIM HJ, HWANG SG.Options for the management of antiviral resistance during hepatitis B therapy:Reflections on battles over a decade[J].Clin Mol Hepatol, 2013, 19 (3) :195-209.
    [24]PIRATVISUTH T, HAN GR, POL S, et al.Comprehensive review of telbivudine in pregnant women with chronic hepatitis B[J].World J Hepatol, 2016, 8 (9) :452-460.
    [25]HAN GR, CAO MK, ZHAO W, et al.A prospective and open-label study for the efficacy and safety of telbivudine in pregnancy for the prevention of perinatal transmission of hepatitis B virus infection[J].J Hepatol, 2011, 55 (6) :1215-1221.
    [26]PAN CQ, HAN GR, JIANG HX, et al.Telbivudine prevents vertical transmission from HBeAg-positive women with chronic hepatitis B[J].Clin Gastroenterol Hepatol, 2012, 10 (5) :520-526.
    [27]KIM YW, KWON JH, CHUNG E, et al.Short term virologic efficacies of telbivudine versus entecavir against hepatitis B-related hepatocellular carcinoma[J].Gastroenterol Res Pract, 2015, 2015:181065.
    [28]LIAW YF, GANE E, LEUNG N, et al.2-Year GLOBE trial results:telbivudine Is superior to lamivudine in patients with chronic hepatitis B[J].Gastroenterology, 2009, 136 (2) :486-495.
    [29]YU M, JIANG Q, JI Y, et al.The efficacy and safety of antiviral therapy with lamivudine to stop the vertical transmission of hepatitis B virus[J].Eur J Clin Microbiol Infect Dis, 2012, 31 (9) :2211-2218.
    [30]ZHANG H, PAN CQ, PANG Q, et al.Telbivudine or lamivudine use in late pregnancy safely reduces perinatal transmission of hepatitis B virus in real-life practice[J].Hepatology, 2014, 60 (2) :468-476.
    [31]LAI CL, GANE E, LIAW YF, et al.Telbivudine versus Lamivudine in patients with chronic hepatitis B[J].N Engl J Med, 2007, 357 (25) :2576-2588.
    [32]ZHANG ML.One case of sorafenib and adefovir dipivoxil induced hypophosphatemia osteomalacia[J].Chin J Modern Appl Pharm (JAMP) , 2016, 33 (3) :373-374. (in Chinese) 张美玲.索拉非尼与阿德福韦酯合用致低磷血症1例[J].中国现代应用药学, 2016, 33 (3) :373-374.
    [33]BRIGGS GG, FREEMAN RK, YAFFE SJ.Drugs in pregnancy and lactation:A reference guide to fetal and neonatal risk[J].Mayo Clin Proc, 1986, 61 (11) :918-919.
    [34]CHEN CY, TU XL, CHENG QH, et al.Clinical observation of telbivudine's antiviral efficacy and protection against mother-to-infant transmission of chronic hepatitis B during the first trimester of pregnancy[J].Chin J Hepatol, 2015, 23 (1) :9-12. (in Chinese) 陈川英, 涂相林, 程全红, 等.慢性乙型肝炎患者妊娠早期替比夫定抗病毒的疗效及母婴阻断的临床观察[J].中华肝脏病杂志, 2015, 23 (1) :9-12.
    [35]WANG H, JI YY, YAO GB, et al.Two years efficiency of lamivudine and adefovir dipivoxil combined therapy in chronic hepatitis Bpatients[J].Eur Rev Med Pharmacol Sci, 2013, 17 (5) :636-643.
    [36]GREENUP AJ, TAN PK, NGUYEN V, et al.Efficacy and safety of tenofovir disoproxil fumarate in pregnancy to prevent perinatal transmission of hepatitis B virus[J].J Hepatol, 2014, 61 (3) :502-507.
    [37]VODKIN I, PATTON H.Management of Hepatitis B virus infection during pregnancy[J].Minerva Gastroenterol Dietol, 2014, 60 (4) :205-214.
    [38]TARANTAL AF, CASTILLO A, EKERT JE, et al.Fetal and maternal outcome after administration of tenofovir to gravid rhesus monkeys (Macaca mulatta) [J].J Acquir Immune Defic Syndr, 2002, 29 (3) :207-220.
    [39]SIBERRY GK, WILLIAMS PL, MENDEZ H, et al.Safety of tenofovir use during pregnancy:early growth outcomes in HIV-exposed uninfected infants[J].AIDS (London, England) , 2012, 26 (9) :1151-1159.
    [40]BERG T, ZOULIM F, MOELLER B, et al.Long-term efficacy and safety of emtricitabine plus tenofovir DF vs.tenofovir DF monotherapy in adefovir-experienced chronic hepatitis B patients[J].JHepatol, 2014, 60 (4) :715-722.
    [41]PATTERSON SJ, GEORGE J, STRASSER SI, et al.Tenofovir disoproxil fumarate rescue therapy following failure of both lamivudine and adefovir dipivoxil in chronic hepatitis B[J].Gut, 2011, 60 (2) :247-254.
    [42]European Association for the Study of the Liver.EASL clinical practice guidellines:Management of chronic hepatitis B[J].J Hepatol, 2012, 57 (1) :167-185.
    [43]SARIN SK, KUMAR M, LAU GK, et al.Asian-Pacific clinical practice guidelines on the management of hepatitis B:A 2015 update[J].Hepatol Int, 2016, 10 (1) :1-98.
    [44]LI L.Interpretation of clinical guidelines for prevention of mother to child transmission of hepatitis B virus (First Edition) [J/CD].Chin JObstet Gynecol Pediatr:Electron Ed, 2014, 10 (2) :11-15. (in Chinese) 李力.“乙型肝炎病毒母婴传播预防临床指南 (第1版) ”解读[J/CD].中华妇幼临床医学杂志:电子版, 2014, 10 (2) :11-15.
    [45] Obstetrics Group of Obstetrics and Gynecology Branch, Chinese Medical Association.Clinical guidelines for prevention of mother to child transmission of hepatitis B virus (First Edition) [J].Chin JPerinat Med, 2015, 18 (5) :321-325. (in Chinese) 中华医学会妇产科学分会产科学组.乙型肝炎病毒母婴传播预防临床指南 (第1版) [J].中华围产医学杂志, 2015, 18 (5) :321-325.
    [46]YU YC, HOU JL.The highlight of EASL 2017 clinical practice guideline on the management of hepatitis B virus infection[J].JClin Hepatol, 2017, 33 (6) :1017-1032. (in Chinese) 于乐成, 侯金林.2017年欧洲肝病学会临床实践指南:HBV感染的管理 (精粹) [J].临床肝胆病杂志, 2017, 33 (6) :1017-1032.
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Article Metrics

    Article views (1973) PDF downloads(508) Cited by()
    Proportional views
    Related

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return